Munich - Delayed Quote • EUR Novo Nordisk A/S (NOV.MU) Follow Compare 101.56 +1.98 (+1.99%) At close: November 26 at 1:48 PM GMT+1 Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Loading Chart for NOV.MU 1D 5D 4.67% 1M -3.44% 6M -19.13% YTD 8.74% 1Y 5.49% 2Y 77.43% 5Y 297.11% All 4,736.19% Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: NOV.MU View More All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Amgen Dives 5% Despite 'Truly Remarkable' Results For Obesity Treatment Medicare Could Pay for Wegovy. Don’t Count On It. Eli Lilly, Novo Nordisk Stocks Gain as Biden Moves to Expand Coverage of Weight-Loss Drugs Biden Proposal to Cover Obesity Drugs Sets Up Quandary for Trump Amgen Falls as Weight-Loss Shot Results Disappoint Street Amgen shows 20% weight loss in once-monthly injectable MariTide Novo, Lilly shares rise as Biden proposes obesity care coverage Update: Market Chatter: Eli Lilly, Novo Nordisk Press Employers to Cover the Cost of Weight-Loss Drugs Drug Compounders Fight Drugmaker Efforts to Push Them Out of Market for GLP-1 Medications Allurion launches compounded GLP-1 program as FDA aims to end access Novo Nordisk A/S - share repurchase programme Related Tickers GSK GSK plc 34.02 -0.38% LLY Eli Lilly and Company 789.32 +4.55% JNJ Johnson & Johnson 154.52 -0.01% PFE Pfizer Inc. 25.77 -1.53%